Hypereosinophilic Syndrome (HES) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hypereosinophilic Syndrome (HES) Market Outlook

Thelansis’s “Hypereosinophilic Syndrome (HES) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypereosinophilic Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypereosinophilic Syndrome Overview

Hypereosinophilic Syndrome (HES) is a group of disorders characterized by elevated blood eosinophil counts (>1.5 × 109/L) and resultant organ damage, commonly affecting the heart. Initially, the term referred to the combination of peripheral blood eosinophilia and tissue infiltrates leading to dysfunction or damage. The "idiopathic" label reflected the lack of knowledge regarding underlying causes, excluding known diseases such as drug allergies, parasitic infections, cancer, lymphoma and myeloproliferative disorders. Symptoms of HES can vary greatly among patients and include skin rashes, dizziness, memory loss, coughing, shortness of breath, fatigue, fever, and mouth sores. Organ damage or dysfunction occurs due to the release of cytotoxic substances by eosinophils, including eosinophil cationic protein, major basic protein, ribonuclease eosinophil derived neurotoxin, eosinophil peroxidase, and enzymes such as elastase and collagenase. Eosinophils also secrete cytokines and chemokines, contributing to the immune response, and can lead to fibrotic changes due to increased collagen synthesis. Current diagnostic criteria for HES suggest that two distinct mechanisms may underlie chronic, unexplained hypereosinophilia in HES patients. One mechanism involves a sporadic hematopoietic stem cell mutation resulting in clonal expansion of eosinophilic cells, and the other involves an overproduction of eosinophilopoietic cytokines by activated T cells. Classifying HES patients can be challenging and requires specialized laboratory evaluation. Predominant skin symptoms without heart involvement, along with serum hyper IgE or polyclonal hypergammaglobulinemia, may suggest the lymphocytic variant of HES. Treatment options for HES include high-dose oral corticosteroids, interferon alpha, hydroxyurea, and PUVA therapy. Approximately 70% of patients respond to oral prednisone therapy with normalization of eosinophil counts. The 5-year survival rate for HES patients is 80%, with heart failure being the most common cause of death.

• The incidence of HES ranged from 0.04 to 0.17 per 100,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: